Stock ACPH ACACIA PHARMA GROUP PLC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Acacia Pharma Group plc

Equities

ACPH

GB00BYWF9Y76

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration

Latest news about Acacia Pharma Group plc

Eagle Pharmaceuticals Completes Acacia Pharma Acquisition MT
Acacia Pharma's Acquisition by Eagle Pharmaceuticals Closes; Shares Delist MT
Acacia Pharma Group plc(ENXTBR:ACPH) dropped from Next Biotech Index CI
Acacia Pharma's Acquisition by Eagle Pharmaceuticals Nears Completion MT
Eagle Pharmaceuticals, Inc. completed the acquisition of Acacia Pharma Group plc from a group of shareholders. CI
Acacia Pharma Group plc Auditor Raises 'Going Concern' Doubt CI
Acacia Pharma Group plc Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Sector Update: Health Care Stocks Posting Modest Gains Monday MT
Health Care Up on Revival of Demand for Growth Sectors -- Health Care Roundup DJ
Sector Update: Health Care Stocks Still Looking for Monday Direction MT
Sector Update: Health Care MT
FTSE 100 Closes Lower Despite Earlier Hopes on Russia, Ukraine Talks DJ
FTSE 100 Rises, 10Y Gilt Yields Hit Six-Year High as Interest-Rate Rises Loom DJ
FTSE Rises, Rolls-Royce Slides as Takeover Talk Remains Unconfirmed DJ
FTSE 100 Rises on Optimism Over Russia-Ukraine Talks DJ
Eagle Pharmaceuticals to Acquire Acacia Pharma MT
Sterling Weakens Vs In-Favor Dollar, Could Drop Toward $1.30 DJ
Acacia Pharma Accepts $104 Million Takeover Bid from US-Based Eagle Pharmaceuticals MT
Eagle Pharmaceuticals, Inc. entered into an agreement to acquire Acacia Pharma Group plc from a group of shareholders for €89.8 million. CI
Acacia Pharma CFO To Step Down MT
Gary Gemignani to Leave Acacia Pharma Group plc as Chief Financial Officer CI
Acacia Pharma Completes US FDA's Required Study for Post-Operative Drug With No Adverse Events MT
Acacia Pharma Completes Required Barhemsys Clinical Trial DJ
Acacia Pharma Announces Successful Completion of Barhemsys® Post-Approval Requirement Study in Patients with Severe Renal Impairment CI
ANALYST RECOMMENDATIONS : Acceleron Pharma, General Mills, Southwest Airlines, Home Depot, Wizz Air... Our Logo

Chart Acacia Pharma Group plc

Chart Acacia Pharma Group plc
More charts

Company Profile

Acacia Pharma Group plc specializes in the research and development of supportive care medicines. The products are intended to support the side effects of anti-cancer treatments (including nausea and vomiting drugs). At the end of 2021, the group had a portfolio of 3 products, including 1 in phase II of clinical development (APD403; treatment of chemically induced nausea and vomiting) and 2 in pre-launch phase: BARHEMSYS (treatment of nausea and postoperative vomiting) and BYFAVO (benzodiazepine sedative for use in invasive medical procedures in adults, such as colonoscopy and bronchoscopy).
Sector
-
More about the company
  1. Stock Market
  2. Equities
  3. ACPH Stock
  4. News Acacia Pharma Group plc
  5. Acacia Pharma Completes US FDA's Required Study for Post-Operative Drug With No Adverse Events